本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Allogene Therapeutics Inc.

1.13
-0.0400-3.42%
盘后1.130.0001+0.01%19:53 EDT
成交量:733.66万
成交额:809.97万
市值:2.47亿
市盈率:-0.85
高:1.20
开:1.20
低:1.06
收:1.17
数据加载中...
2022/11/02

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]
2022/10/06

重要事件披露

8-K - Current report
2022/09/21

重要事件披露

8-K - Current report
2022/08/09

重要事件披露

8-K - Current report
2022/08/09

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]
2022/07/12

重要事件披露

8-K - Current report
2022/06/17

重要事件披露

8-K - Current report
2022/05/04

重要事件披露

8-K - Current report
2022/05/04

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]
2022/04/07

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/02/23

重要事件披露

8-K - Current report
2022/02/23

年度报告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2022/02/23

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2022/02/14

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/14

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/11

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/11

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/10

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/01/18

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2021/10/04

持股变动声明

4 - Statement of changes in beneficial ownership of securities